|
Accreditation |
2.5 AMA PRA Category 1 Credit(s)™.
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2. |
Target Audience |
This activity will be directed to rheumatologists, gastroenterologists, dermatologists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals interested in or using biologic therapeutics in autoimmune and inflammatory disorders. |
Description |
This activity was presented at the Cleveland Clinic Richard J. Fasenmyer Center of Clinical Immunology Biologic Therapies for Autoimmune and Inflammatory Disease States Summit. The reviewed advances in biologic therapies for autoimmune diseases. |
Objectives |
At the conclusion of this activity, the participant will be able to:
- Recognize the most common infections associated with the use of TNF-α inhibitors.
- List preventative screening measures to reduce infectious complications associated with the use of TNF-α inhibitors.
- Identify risks for opportunistic infections across available agents and classes.
- Identify granulomatous infections and treatment with available agents.
- Identify data on hepatic toxicity form biologic anti-rheumatic therapies.
|
Activity Director |
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic and Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology |
Faculty |
Marc D. Cohen, MD
Jack Cush, MD
Jerrold J. Ellner, MD
Thomas File, MD
Richard Rudick, MD |
Faculty Disclosure |
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO |
|
Consulting, Teaching and Speaking
|
Genentech |
|
Teaching and Speaking |
Abbott; Amgen; Wyeth |
| |
| Marc Cohen, MD |
|
Teaching and Speaking |
Abbott; BMS; Centocor
|
| |
Consulting, Teaching and Speaking: |
Amgen; Genentech |
| |
Consulting |
Wyeth |
| |
| Jack Cush, MD |
|
Consulting, Teaching and Speaking |
Abbott Pharmaceuticals |
|
Consulting |
Wyeth |
| |
Consulting and Independent Contractor |
Centocor; UCB |
| |
| Thomas File, MD |
|
Research, Consulting and Speaker’s Bureau |
Bayer; Binax Incorporated; GlaxoSmithKline; Merck; Ortho-McNeil; Oscient; Pfizer;
Sanofi-Aventis; Schering-Plough; Wyeth |
| |
The following faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
|
Jerrold J. Ellner, MD
Richard Rudick, MD |
|
| Estimated Time of Completion |
2 hours 30 minutes |
The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for support of this activity from:
 |
 |
 |
| Genentech and Biogen Idec. |
 |
 |
Gold Level

This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education and UNITECH Communications®.
Contact Information | Privacy Policy | Disclaimer
Copyright © 2008 The Cleveland Clinic Foundation. All Rights Reserved. |